TWI315740B - - Google Patents

Info

Publication number
TWI315740B
TWI315740B TW091118623A TW91118623A TWI315740B TW I315740 B TWI315740 B TW I315740B TW 091118623 A TW091118623 A TW 091118623A TW 91118623 A TW91118623 A TW 91118623A TW I315740 B TWI315740 B TW I315740B
Authority
TW
Taiwan
Prior art keywords
cell
growth factor
binding
substance
substance capable
Prior art date
Application number
TW091118623A
Other languages
English (en)
Inventor
Sagawa Hiroaki
Ideno Mitsuko
Kato Ikunoshin
Original Assignee
Takara Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takara Bio Inc filed Critical Takara Bio Inc
Application granted granted Critical
Publication of TWI315740B publication Critical patent/TWI315740B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464486—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464491—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/12—Hepatocyte growth factor [HGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/58—Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/905—Hyaluronic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW091118623A 2001-08-15 2002-08-15 TWI315740B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001246747 2001-08-15
JP2001376966 2001-12-11
JP2002084428 2002-03-25

Publications (1)

Publication Number Publication Date
TWI315740B true TWI315740B (zh) 2009-10-11

Family

ID=27347333

Family Applications (3)

Application Number Title Priority Date Filing Date
TW095148473A TW200718784A (en) 2001-08-15 2002-08-15 Method of extended culture for antigen-specific cytotoxic T lumphocytes
TW091118623A TWI315740B (zh) 2001-08-15 2002-08-15
TW095111709A TWI311586B (en) 2001-08-15 2002-08-15 Method of extended culture for antigen-specific cytotoxic t lumphocytes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TW095148473A TW200718784A (en) 2001-08-15 2002-08-15 Method of extended culture for antigen-specific cytotoxic T lumphocytes

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW095111709A TWI311586B (en) 2001-08-15 2002-08-15 Method of extended culture for antigen-specific cytotoxic t lumphocytes

Country Status (9)

Country Link
US (1) US7910368B2 (zh)
EP (2) EP1424387B1 (zh)
JP (3) JP4949607B2 (zh)
KR (2) KR100888915B1 (zh)
CN (2) CN101633907B (zh)
AT (1) ATE429486T1 (zh)
DE (1) DE60232083D1 (zh)
TW (3) TW200718784A (zh)
WO (1) WO2003016511A1 (zh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1312670A4 (en) * 2000-08-16 2005-11-30 Takara Bio Inc METHOD FOR THE EXTENSIVE CULTURE OF ANTIGEN-SPECIFIC CYTOTOXIC T CELLS
TW200718784A (en) 2001-08-15 2007-05-16 Takara Bio Inc Method of extended culture for antigen-specific cytotoxic T lumphocytes
ATE491021T1 (de) * 2002-03-25 2010-12-15 Takara Bio Inc Verfahren zur produktion eines zytotoxischen lymphozyten
EP1666589B1 (en) 2003-08-22 2010-02-17 Takara Bio Inc. Process for producing cytotoxic lymphocytes
KR101279172B1 (ko) * 2005-08-17 2013-06-27 다카라 바이오 가부시키가이샤 림프구의 제조 방법
JP4741906B2 (ja) * 2005-08-31 2011-08-10 タカラバイオ株式会社 リンパ球の製造方法
KR101408565B1 (ko) * 2005-09-30 2014-06-17 다카라 바이오 가부시키가이샤 Ｔ 세포 집단의 제조 방법
EP2028266A4 (en) * 2006-06-09 2010-08-11 Takara Bio Inc PROCESS FOR PRODUCING LYMPHOCYTES
WO2008111430A1 (ja) * 2007-03-09 2008-09-18 Takara Bio Inc. γδＴ細胞集団の製造方法
US20100247579A1 (en) * 2007-05-11 2010-09-30 Hiroshi Shiku Therapeutic agent for cancer
US20110027242A1 (en) * 2008-03-27 2011-02-03 Takara Bio Inc. Method for production of transfected cell
EP2236517A1 (en) 2009-03-31 2010-10-06 Takara Bio, Inc. Anti-fibronectin fragment monoclonal antibody
WO2011024791A1 (ja) 2009-08-25 2011-03-03 タカラバイオ株式会社 レチノイン酸存在下でのｔ細胞集団の製造方法
KR101110866B1 (ko) * 2009-12-29 2012-02-20 재단법인 포항산업과학연구원 몰드 동판 가공 장치
JP5805089B2 (ja) * 2010-08-10 2015-11-04 タカラバイオ株式会社 細胞集団の製造方法
JP2014510926A (ja) * 2011-04-07 2014-05-01 ザ スクリップス リサーチ インスティテュート 細胞巨大分子の発現を調節する化合物のハイスループットスクリーニング
CN103013914B (zh) * 2012-12-13 2014-12-03 吉林省拓华生物科技有限公司 体外培养杀伤性t细胞的方法
US20150079626A1 (en) * 2013-03-19 2015-03-19 Lsip, Llc Method of obtaining a cell population containing cancer stem cells
CN112175911B (zh) 2014-05-15 2023-10-13 新加坡国立大学 经修饰的自然杀伤细胞及其用途
SG11201908337VA (en) 2017-03-27 2019-10-30 Nat Univ Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
CA3107421A1 (en) * 2018-08-10 2020-02-13 Kyoto University Method for producing cd3-positive cell

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8516421D0 (en) 1985-06-28 1985-07-31 Biotechnology Interface Ltd Fibronectins
US5019646A (en) 1987-08-25 1991-05-28 Regents Of The University Of Minnesota Polypeptides with fibronectin activity
US5057423A (en) 1987-12-18 1991-10-15 University Of Pittsburgh Method for the preparation of pure LAK-active lymphocytes
JP2561131B2 (ja) 1988-06-30 1996-12-04 寳酒造株式会社 細胞接着活性ポリペプチド
GB8909916D0 (en) 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
US5198423A (en) 1989-05-26 1993-03-30 Takara Shuzo Co., Ltd. Functional polypeptide containing a cell binding domain and a heparin binding domain of fibronectin
US5188959A (en) 1989-09-28 1993-02-23 Trustees Of Tufts College Extracellular matrix protein adherent t cells
JP3104178B2 (ja) 1990-03-30 2000-10-30 寶酒造株式会社 機能性ポリペプチド
JPH04297494A (ja) 1991-03-26 1992-10-21 Fuji Photo Film Co Ltd ペプチド誘導体とその用途
JP2729712B2 (ja) 1991-04-23 1998-03-18 寳酒造株式会社 機能性ポリペプチド
JPH07102131B2 (ja) 1991-07-15 1995-11-08 日本石油株式会社 ヒトリンパ球の癌細胞に対する傷害活性を高める方法
JPH06306096A (ja) 1993-02-26 1994-11-01 Fuji Photo Film Co Ltd ペプチド誘導体及びその用途
GB9315810D0 (en) 1993-07-30 1993-09-15 Univ London Stabilised materials
DE4336399A1 (de) 1993-10-26 1995-04-27 Augustinus Dr Med Bader Verfahren zur Verbesserung der Matrixbedingungen bipolar adhärierter Hepatozyten und zur Herstellung eines entsprechend konfigurierten Zellkulturkits
US6821778B1 (en) * 1993-12-01 2004-11-23 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells
DE4412794A1 (de) 1994-04-14 1995-12-14 Univ Ludwigs Albert Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens
GB9413029D0 (en) 1994-06-29 1994-08-17 Common Services Agency Stem cell immobilisation
CN1116549A (zh) * 1994-08-09 1996-02-14 中国医学科学院肿瘤研究所 新型高亲和性肿瘤杀伤细胞(t-ak细胞)制剂
US5827642A (en) * 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5824547A (en) 1994-11-29 1998-10-20 Takara Shuzo Co., Ltd. Method for production of transfected cells
EP0797450A4 (en) 1994-12-01 2000-02-02 New England Deaconess Hospital IN VITRO T-LYMPHOPOIESE SYSTEM
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
EP0824594B1 (en) 1995-05-04 2005-04-06 The United States of America as Representend by The Secretary of the Navy Improved methods for transfecting t cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
JPH0925299A (ja) 1995-07-13 1997-01-28 Sumitomo Electric Ind Ltd Ｃｄ４４リガンド
EP0852618A1 (en) 1995-07-25 1998-07-15 Celltherapy Inc. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
ATE325533T1 (de) * 1995-09-29 2006-06-15 Univ Indiana Res & Tech Corp Verfahren zum verbesserten virusvermittelten dns- transfer unter verwendung von molekülen mit virus-und zellbindenden domänen
CN100390290C (zh) 1995-11-13 2008-05-28 宝生物工程株式会社 用逆转录病毒将基因转入靶细胞的方法
US6734014B1 (en) * 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
AU726198B2 (en) * 1996-03-04 2000-11-02 Targeted Genetics Corporation Modified rapid expansion methods ("modified-REM") for in vitro propagation of T lymphocytes
EP0904350B1 (en) * 1996-03-04 2010-08-04 Calyx Bio-Ventures Inc. Modified rapid expansion methods ("modified-rem") for in vitro propagation of t lymphocytes
EP0929664A1 (en) 1996-09-23 1999-07-21 Ontogeny, Inc. Hematopoietic stem cells and methods for generating such cells
JP2001509677A (ja) 1997-01-31 2001-07-24 エピミューン，インコーポレイティド Ｃｔｌを活性化するためのペプチドおよびペプチド担持抗原提示細胞
AU2010699A (en) 1997-12-24 1999-07-19 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for theiruse
WO2000056368A1 (fr) 1999-03-23 2000-09-28 Takara Shuzo Co., Ltd. Therapeutique genique
JP3904374B2 (ja) 2000-02-29 2007-04-11 独立行政法人科学技術振興機構 キラー活性を増強したリンパ球
CN1314414A (zh) * 2001-03-16 2001-09-26 中国人民解放军第四军医大学 一种新的分子量为140kDa的活化T细胞表面抗原
TW200718784A (en) 2001-08-15 2007-05-16 Takara Bio Inc Method of extended culture for antigen-specific cytotoxic T lumphocytes
ATE491021T1 (de) 2002-03-25 2010-12-15 Takara Bio Inc Verfahren zur produktion eines zytotoxischen lymphozyten

Also Published As

Publication number Publication date
EP2070542A3 (en) 2010-01-06
JP2008278892A (ja) 2008-11-20
US20050042208A1 (en) 2005-02-24
DE60232083D1 (de) 2009-06-04
JP4332573B2 (ja) 2009-09-16
KR100858857B1 (ko) 2008-09-17
EP1424387A1 (en) 2004-06-02
CN100510060C (zh) 2009-07-08
JP4472764B2 (ja) 2010-06-02
EP1424387A4 (en) 2005-10-12
TW200626725A (en) 2006-08-01
JP4949607B2 (ja) 2012-06-13
CN101633907B (zh) 2012-09-05
TWI311586B (en) 2009-07-01
JPWO2003016511A1 (ja) 2004-12-02
JP2008035864A (ja) 2008-02-21
CN101633907A (zh) 2010-01-27
ATE429486T1 (de) 2009-05-15
KR100888915B1 (ko) 2009-03-16
EP2070542A2 (en) 2009-06-17
US7910368B2 (en) 2011-03-22
WO2003016511A1 (en) 2003-02-27
EP1424387B1 (en) 2009-04-22
KR20070122579A (ko) 2007-12-31
TW200718784A (en) 2007-05-16
CN1543501A (zh) 2004-11-03
KR20040030093A (ko) 2004-04-08

Similar Documents

Publication Publication Date Title
TWI315740B (zh)
DE60034566D1 (de) Peptidakzeptor ligationsverfahren
EA200800996A1 (ru) Способ получения т-клеточной популяции
CY1110695T1 (el) Μεθοδοι για την δημιουργια υψηλου τιτλου ανευ-βοηθου παρασκευασματων απελευθερωμενων ανασυνδυασμενων aav φορεων
MXPA03004793A (es) Roedores transgenicos transcromosomales para elaborar anticuerpos humnanos.
AU2002246702A1 (en) Method of screening for gpr40 ligands
ATE346938T1 (de) Polyketid synthase enzyme und rekombinante dna konstrukte dafür, zur herstellung von mit fk-506 und fk-520 verwandten verbindungen
WO1997015662A3 (en) Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
DE69808751D1 (de) Kohlenwasserstoffsynthese unter verwendung von restgasen zur katalysatorwiederbelebung
TW200741000A (en) Method of producing lymphocytes
IL143670A0 (en) Methods for the expression of active protein-immunoglobulin fusions, active protein-immunoglobulin fusions obtained thereby and pharmaceutical compositions containing the same
DE60213803D1 (en) Happier mapping
ATE458046T1 (de) Verfahren zur herstellung zytotoxischer lymphozyten
ATE555194T1 (de) Methode zur herstellung von proliferierenden und differenzierenden zelllinien
HK1056292A1 (en) Method of culturing zooplankton, apparatus for culturing by the same, and culture obtained by the same.
HUP0204421A2 (en) Chemically-modified supports and supported catalyst systems prepared therefrom
AU2001278700A1 (en) Method of culturing human chondrocytes
WO2003051314A3 (en) Antibiotic compounds
WO1997039107A3 (en) Methods for increasing the maturation of cells
GB9909229D0 (en) Enantiomers of mercapto lactones and processes for their synthesis
PT1064265E (pt) Sintese de 3-amino-2-cloro-4-metilpiridina a partir de malononitrilo e acetona
DK1238057T3 (da) Fremgangsmåde til produktion af vedhæftende dyreceller
ATE466847T1 (de) Verfahren zur herstellung von 14-beta- hydroxybaccatin-iii-1,14-carbonat
ATE537160T1 (de) Verfahren zur herstellung von 14beta- hydroxybaccatin-iii-1,14-carbonat
ATE393213T1 (de) Dendritische zelle mit alpha-glycosylceramid- derivat und antigen zur verwendung bei der unterdrückung von immunreaktionen

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees